143 results
SUPPL
IMVIQ
IMV Inc.
20 Dec 22
Supplemental materials (foreign)
6:02am
in patent or other intellectual property rights; public concern as to the safety and efficacy of drugs that the Corporation and its competitors develop … that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of Keytruda®, or safety, efficacy, manufacturing or supply
SUPPL
IMVIQ
IMV Inc.
19 Dec 22
Supplemental materials (foreign)
5:26pm
intellectual property rights; public concern as to the safety and efficacy of drugs that the Corporation and its competitors develop; and shareholder … to the risks that the FDA, EMA or other comparable foreign regulatory authorities could revoke approval of Keytruda®, or safety, efficacy
6-K
EX-99.2
IMVIQ
IMV Inc.
10 Nov 22
Report of Foreign Private Issuer for the Month of November, 2022
4:09pm
immunotherapeutic platform to offer better treatments for solid and hematological cancers. The favorable safety outcomes shown by our lead product candidate … %) and is associated with reduced overall survival13.
In 2021, we completed the DeCidE1 phase 2 trial which evaluated safety and effectiveness of MVP-S
6-K
EX-99.1
IMVIQ
IMV Inc.
28 Oct 22
Notice of Special Meeting of Shareholders
4:41pm
to ensure the health and safety of our shareholders and employees, IMV has elected to hold the Meeting as a completely virtual meeting, which
6-K
EX-99.2
IMVIQ
IMV Inc.
28 Oct 22
Notice of Special Meeting of Shareholders
4:41pm
and necessary step to ensure the health and safety of our shareholders and employees, IMV has elected to hold the Meeting as a completely virtual meeting, which
6-K
EX-99.1
qf4c66seksmi pbt323
12 Aug 22
IMV Inc. Announces Second Quarter 2022 Financial and Operational Results
1:44pm
6-K
EX-99.2
4af n52jhnrnex8117
11 Aug 22
Report of Foreign Private Issuer for the Month of August, 2022
7:13am
6-K
EX-99.2
22bdx5
5 Aug 22
Current report (foreign)
4:12pm
SUPPL
qefr6f1
5 Aug 22
Supplemental materials (foreign)
3:00pm
SUPPL
5q6r xdbq
4 Aug 22
Supplemental materials (foreign)
5:13pm
F-10/A
662e6n7y
25 Jul 22
Registration of securities (Canada) (amended)
12:20pm
F-10
driys 4lbty4w653zud
11 Jul 22
Registration of securities (Canada)
3:05pm
6-K
EX-99.1
g5o57xmg9i
3 Jun 22
Notice of Annual and Special Meeting of Shareholders
9:00am
6-K
EX-99.2
mqpl6mlvi2n
3 Jun 22
Notice of Annual and Special Meeting of Shareholders
9:00am
6-K
EX-99.1
p3z4 r1gzv5
13 May 22
IMV Inc. Announces First Quarter 2022 Financial and Operational Results
9:24am
6-K
EX-99.1
6y8lk8ep 8zyo5x
13 May 22
Report of Foreign Private Issuer for the Month of May, 2022
7:12am
6-K
EX-99.2
m1za358r
13 May 22
Report of Foreign Private Issuer for the Month of May, 2022
7:12am
6-K
EX-99.1
4cjf8x
11 Apr 22
IMV Inc. Presents Clinical Benefit of MVP-S in Combination with Pembrolizumab in Bladder Cancer at the AACR Annual Meeting
9:01am
40-F
EX-99.3
7pzix08 4tudo0z
17 Mar 22
Annual report (Canada)
7:06am
40-F
p0ij6o qgw5c43hkbpn
17 Mar 22
Annual report (Canada)
7:06am